| CAPOX Regimen studied in …STUDIED_INderived10 of 66show all (up to 200) |
|---|
| → studied in | NCT07700979Phase 3 · recruiting Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma · 66 trials list this drug (37 active) | — | — | Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05482893Phase 1/Phase 2 · recruiting Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) · 66 trials list this drug (37 active) | — | — | Malignant Biliary Tract Neoplasm,Malignant Colorectal Neoplasm,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07221357Phase 2/Phase 3 · recruiting A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer · 66 trials list this drug (37 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07315750Phase 3 · recruiting A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. · 66 trials list this drug (37 active) | — | — | Gastric Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07728019Phase 2 · recruiting Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM · 66 trials list this drug (37 active) | — | — | Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07132463Phase 3 · recruiting Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study · 66 trials list this drug (37 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06246344Phase 3 · active not recruiting Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer · 66 trials list this drug (37 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07819604Phase 2 · not yet recruiting Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer · 66 trials list this drug (37 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07821333Phase 2 · active not recruiting Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II-III · 66 trials list this drug (37 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07221149Phase 2/Phase 3 · recruiting A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) · 66 trials list this drug (37 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |